CA3245978A1 - DEUTERATED ANALOGUES OF ERK PYRROLUS INHIBITORS, THEIR SYNTHESIS AND INTERMEDIARIES - Google Patents

DEUTERATED ANALOGUES OF ERK PYRROLUS INHIBITORS, THEIR SYNTHESIS AND INTERMEDIARIES

Info

Publication number
CA3245978A1
CA3245978A1 CA3245978A CA3245978A CA3245978A1 CA 3245978 A1 CA3245978 A1 CA 3245978A1 CA 3245978 A CA3245978 A CA 3245978A CA 3245978 A CA3245978 A CA 3245978A CA 3245978 A1 CA3245978 A1 CA 3245978A1
Authority
CA
Canada
Prior art keywords
formula
compound
pct
deuterium
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3245978A
Other languages
English (en)
French (fr)
Inventor
Gary DeCrescenzo
Martin TERESK
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of CA3245978A1 publication Critical patent/CA3245978A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3245978A 2022-03-24 2023-03-24 DEUTERATED ANALOGUES OF ERK PYRROLUS INHIBITORS, THEIR SYNTHESIS AND INTERMEDIARIES Pending CA3245978A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
US63/323,221 2022-03-24
PCT/US2023/064908 WO2023183905A2 (en) 2022-03-24 2023-03-24 Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
CA3245978A1 true CA3245978A1 (en) 2023-09-28

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3245978A Pending CA3245978A1 (en) 2022-03-24 2023-03-24 DEUTERATED ANALOGUES OF ERK PYRROLUS INHIBITORS, THEIR SYNTHESIS AND INTERMEDIARIES

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
IL315702A (en) 2024-11-01
JP2025509969A (ja) 2025-04-11
WO2023183905A3 (en) 2023-10-26
TW202400572A (zh) 2024-01-01
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
CN119212985A (zh) 2024-12-27
MX2024011415A (es) 2024-09-24

Similar Documents

Publication Publication Date Title
JP7637459B2 (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
USRE49500E1 (en) Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
TWI405761B (zh) 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
CN102596960B (zh) 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
CA3050625C (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
IL191776A (en) Carbonylamino pyrrolopyrazole compounds , pharmaceutical compositions comprising them and use of the compounds in the preparation of medicaments
CN111386260A (zh) 磺酰胺化合物及其用途
CN104507946A (zh) 氘代依鲁替尼
TW200520758A (en) Novel pharmaceuticals
CN102459270A (zh) Janus激酶3的哌啶抑制剂
US10925876B2 (en) Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
EP2470542A2 (en) Preparation of sitagliptin and salts thereof
CN112469473A (zh) 作为magl抑制剂的杂环螺环化合物
US20250026733A1 (en) Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto
JP2021529819A (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
EP3679039A1 (en) Tyrosine analogues derivatives as rho- kinase inhibitors
US11760751B2 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
TWI902351B (zh) 嘧啶胺類nuak抑制劑及其製備方法和用途
HK40118078A (zh) Erk的吡咯抑制剂的氘代类似物、其合成及其中间体
WO2007039578A1 (en) Imidazolyl-substituted azabenzophenone compounds
WO2007039580A1 (en) Imidazolyl-substituted benzophenone compounds
JP2004514678A (ja) ベンズイミダゾール誘導体、それらの製造ならびにそれらの治療的適用
CN117185987A (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
WO2008031788A1 (en) Aminoazepine derivatives as highly efficient inhibitors of the inducible nitric oxide synthase

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240913

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240916

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240916

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423